Researchers identify bone-forming cells as the driver of scoliosis caused by a genetic disorder, which can be prevented ...
Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people. These ...
Pasithea Therapeutics Corp. has announced the successful enrollment and initial dosing of three subjects in Cohort 6 of its Phase 1 clinical trial for PAS-004, a candidate for treating ...
When the NF1 gene was discovered in 1990, it was quickly learned that the gene product functions as a regulator of a protein called Ras. Ras is a key component of a cell signaling pathway that ...
Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people. These ...
The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults and children. The drug, developed by SpringWorks Therapeutics, is the first ...